Guide

Veterinary Pharma Manufacturing Readiness: One Spine Across Five Frameworks

Veterinary pharmaceutical and biologic manufacturers operate under a regulatory family that overlaps human pharma at the cGMP base but diverges sharply at the boundaries. A US animal drug manufacturer runs under FDA Center for Veterinary Medicine (CVM) via 21 CFR 514 (NADA/ANADA), 21 CFR 211 cGMP, and the relevant guidance for industry. A US veterinary biologics manufacturer runs under USDA APHIS Center for Veterinary Biologics via 9 CFR 101–124 (notably Part 113 standards). Medicated feed mills run under 21 CFR 225/558 and the Veterinary Feed Directive. International harmonisation runs through VICH guidelines. Extralabel use at the prescribing veterinarian sits under AMDUCA and feeds back into residue/withdrawal evidence the manufacturer must support. This hub maps the five readiness paths V5 supports and links to the detailed spoke guides.

Start free trial Free trial, no credit card, onboard in days, not months.

The framework family: CVM vs CVB and why agency choice drives everything

The single most consequential decision in US veterinary manufacturing is which centre regulates the product. FDA-CVM regulates animal drugs (chemical, hormonal, antimicrobial) under 21 CFR 211 cGMP and 21 CFR 514 submissions. USDA-APHIS-CVB regulates veterinary biologics (vaccines, bacterins, antitoxins, diagnostic kits) under 9 CFR 101–124. The two agencies run different submission pathways, different inspection models, and different post-market obligations. A combination product or a product on the boundary (e.g. some immunomodulators) requires a centre-of-jurisdiction determination before submission strategy can be set.

The five readiness paths and where to start

Path 1 — FDA-CVM animal drugs: 21 CFR 514 NADA/ANADA + 21 CFR 211 cGMP. Path 2 — USDA-APHIS veterinary biologics: 9 CFR 113 standards + outline of production + serial release. Path 3 — Medicated feed and VFD: 21 CFR 225/558 + VFD distribution and recordkeeping. Path 4 — International harmonisation: VICH GL guidelines (GL2 validation, GL9 GCP, GL49 residue) for multi-region submissions. Path 5 — AMDUCA extralabel and residue evidence: the prescribing-side discipline that drives label restrictions and withdrawal data. Start with the path that owns your primary submission — then layer the others as your portfolio expands.

Where vet pharma diverges from human pharma

Five structural divergences shape the operating model. First, target species variability — a label may cover cattle, swine, poultry, dogs and cats with species-specific dosing, withdrawal and pharmacovigilance data. Second, autogenous biologics — USDA-CVB authorises non-licensed autogenous vaccines for specific herd outbreaks under 9 CFR 113.113, a pathway with no human pharma analogue. Third, residue and withdrawal — food-producing species require validated tissue/milk/egg withdrawal evidence the human framework does not contemplate. Fourth, medicated feed — the manufacturer-distributor-veterinarian-producer chain under VFD has no parallel in human prescribing. Fifth, MUMS — Minor Use Minor Species pathways at CVM offer accelerated routes for small-population indications.

Pharmacovigilance and adverse event reporting across agencies

FDA-CVM Form 1932 adverse event reports cover animal drugs with 15-day expedited reporting for serious unexpected events. USDA-CVB serial release reporting and adverse event reports cover biologics on their own forms and clocks. EMA EudraVigilance Veterinary covers EU products under VICH GL24/GL29. A manufacturer with multi-region multi-agency reach runs three pharmacovigilance regimes simultaneously — the case intake is shared, the reporting destinations and clocks are not.

A 90-day multi-path readiness path

Days 1–15: framework inventory — which paths your products actually run, where overlays interact, and where the centre-of-jurisdiction needs refresh. Days 16–35: primary path internal audit (CVM or CVB). Days 36–55: secondary overlays — medicated feed, VICH international, autogenous if applicable. Days 56–75: pharmacovigilance multi-agency reporting clock audit. Days 76–85: residue/withdrawal evidence currency for food-producing species. Days 86–90: integrated management review and inspection readiness rehearsal.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Multi-framework vet QMS

One spine across CVM, CVB, VFD, VICH.

Species-stratified records

Label, withdrawal and PV per species on one document.

Multi-agency PV

Right form, right clock per agency.

Industries this hits hardest

Veterinary pharma

Frequently asked

Is FDA-CVM cGMP the same as 21 CFR 211 for human drugs?

Yes — 21 CFR 211 cGMP applies to both. The differences are in the submission pathway (514 NADA/ANADA vs 314 NDA/ANDA), label requirements (species, route, withdrawal), and post-market reporting (Form 1932 vs MedWatch). The manufacturing controls themselves are the same regulation.

We make a vaccine — CVM or CVB?

Veterinary vaccines are CVB. Animal drugs (including chemical, hormonal and antimicrobial products) are CVM. The split is by product type, not by company. A combination product or a novel immunotherapy may need a formal centre-of-jurisdiction determination.

Does VICH harmonisation actually reduce work for multi-region submissions?

Yes for the technical sections (GL2 stability, GL9 GCP, GL49 residue methods) which the major regions accept on the harmonised standard. No for the administrative submissions themselves — each region still has its own dossier format, fees and review process.

Is autogenous vaccine manufacturing GMP?

It is regulated under 9 CFR 113.113 with a defined set of requirements — herd specificity, veterinarian prescription, defined manufacturing facility — but it is not full licensed-product 9 CFR 113 standards. A manufacturer doing both licensed and autogenous runs the higher standard on shared facilities.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →